The Global Leukemia drugs market size stood at USD 12.3 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
The leukemia therapeutics market is mainly driven by the rising burden of leukemia cases, high unmet medical need for cancer therapy and rising investment in healthcare sectors. According to the American Cancer Society, in the United States there were approximately 61,780 new cases of leukemia in 2019.
Among them, the number of new cases of acute myeloid leukemia (AML) were around 21,450. AML is thus considered as one of the most common types of leukemia in adults. Hence the overall statistics shows that there is a huge number of people that are prone to suffer from leukemia, and which may directly impact the growth of the market in the forecast period.
There has been a tremendous increase in cell-based research activities over the past decade. Increasing research in the field of regenerative medicine for the treatment of leukemia and growing awareness on personalized medicine have also resulted in the growth of this market. In addition to it, the growth in this market is driven by the high prevalence and incidence of leukemia and the rising geriatric population. According to the Leukemia & Lymphoma Society, an estimated 381,774 people are living with or in remission from leukemia in the US